Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA9 | Q16790 | 1/20 | 0.53 |
| ▸ | MAOB | P27338 | 16/20 | 0.47 |
| ▸ | MAOA | P21397 | 14/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.46 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.46 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.46 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.46 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.43 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.43 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.43 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18500392 | 0.91 | MAPT (0.49) | CA9MAOBMAOANPC1MAPK13 | |
| SCHEMBL18500396 | 0.88 | TBXAS1 (0.54) | MAOBMAOANPC1MAPK13MAPK12 | |
| SCHEMBL29754329 | 0.82 | CA9 (0.57) | CA9MAOBMAOANPC1MAPK13 | |
| SCHEMBL2611058 | 0.82 | CA9 (0.57) | CA9MAOBMAOANPC1MAPK13 | |
| SCHEMBL20032320 | 0.80 | KIF11 (0.58) | MAOBMAOANPC1MAPK13MAPK12 | |
| SCHEMBL2218608 | 0.79 | CA9 (0.54) | CA9MAOBMAOANPC1MAPK13 | |
| SCHEMBL29337400 | 0.79 | CA9 (0.58) | CA9MAOBMAOANPC1MAPK13 | |
| SCHEMBL18500453 | 0.79 | MAPT (0.49) | TBXAS1PDE3BPDE3A | |
| SCHEMBL4259653 | 0.76 | CA9 (0.50) | CA9MAOBMAOANPC1MAPK13 | |
| SCHEMBL1885817 | 0.76 | CA9 (0.50) | CA9MAOBMAOANPC1MAPK13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200216431-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | RIGEL PHARMACEUTICALS, INC. (US) | 2020-07-09 | — | — | US | disclosed |
| US-10556891-B2 | Compositions and methods for inhibition of the JAK pathway | RIGEL PHARMACEUTICALS, INC. (US) | 2020-02-11 | — | — | US | disclosed |
| US-9566283-B2 | Compositions and methods for inhibition of the JAK pathway | RIGEL PHARMACEUTICALS, INC. (US) | 2017-02-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200216431-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | JAK3, JAK2, JAK1 | CA9 4511/4885MAOB 2579/4885MAOA 3861/4885 |
| US-10556891-B2 | Compositions and methods for inhibition of the JAK pathway | JAK3, JAK2, JAK1 | CA9 4511/4885MAOB 2579/4885MAOA 3861/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.